Business · 04/03/2019Updated: 10/17/2026 · 1 min read
FDA Evaluates Bulk Drug Substances for Clinical Need Under Section 503B of the FD&C Act
Summary
The FDA is reviewing a list of bulk drug substances that have been nominated for inclusion due to clinical need, and has identified two substances that will not be included at this time, while others are under consideration for future notices.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →